secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047678
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune
--------------------------------------------------------------------------------

- Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.
- Collaboration revenue $1.6M in Q4 vs $1.8M a year ago; full year rev $9.3M from Ono Pharma deal.
- R&D spend cut to $7.2M (Q4) from $10.9M; cash and equivalents $22.5M as of Dec 31, 2024.
- Regained worldwide rights to CUE-401 (autoimmune lead); prioritizing autoimmune over oncology.
- Appointed Lucinda Warren (CBO), Dr. Daniel Baker (Interim CDO), Dr. Pasha Sarraf (Board).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/0000950170-25-047678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/cue-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer